| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.23 | 2e-05 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.22 | 2e-05 |
| mRNA | Vinblastine | GDSC1000 | pan-cancer | AAC | -0.16 | 3e-05 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-05 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.21 | 5e-05 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0001 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.2 | 0.0001 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | 0.22 | 0.0001 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0002 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0002 |